A5012694556- Radiomics and Machine Learning in Medical Imaging
- AI in cancer detection
- Cancer Genomics and Diagnostics
- Advanced Proteomics Techniques and Applications
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Bladder and Urothelial Cancer Treatments
- Genetic factors in colorectal cancer
- COVID-19 and healthcare impacts
- CAR-T cell therapy research
- Neonatal and fetal brain pathology
- Childhood Cancer Survivors' Quality of Life
- Tuberous Sclerosis Complex Research
- Colorectal Cancer Treatments and Studies
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
- Healthcare cost, quality, practices
- Acute Myeloid Leukemia Research
- PARP inhibition in cancer therapy
- Migraine and Headache Studies
- Urinary and Genital Oncology Studies
- Neurological Complications and Syndromes
- Gene expression and cancer classification
- Histone Deacetylase Inhibitors Research
- Hemoglobinopathies and Related Disorders
Scripps Clinic
2017-2022
Scripps Institution of Oceanography
2017-2019
Cancer Clinic
2017-2018
Scripps Mercy Hospital
2017
Scripps Health
2016-2017
Angeles Clinic and Research Institute
2017
Cedars-Sinai Medical Center
2017
University of California, San Diego
2009-2011
Despite significant advances in breast imaging, the ability to detect cancer (BC) remains a challenge. To address unmet needs of current BC detection paradigm, 2 prospective clinical trials were conducted develop blood-based combinatorial proteomic biomarker assay (Videssa Breast) accurately and reduce false positives (FPs) from suspicious imaging findings. Provista-001 Provista-002 (cohort one) enrolled Breast Imaging Reporting Data System 3 or 4 women aged under 50 years. Serum was...
With improvements in breast cancer imaging, there has been a corresponding increase false-positives and avoidable biopsies. There is need to better differentiate when biopsy warranted determine appropriate follow-up. This study describes the design clinical performance of combinatorial proteomic biomarker assay (CPBA), Videssa Breast, women over age 50 years. A BI-RADS 3, 4, or 5 assessment was required for trial enrollment. Serum collected prior subjects were followed 6-12 months clinically...
Sleep disruption is a common complaint in breast cancer patients receiving chemotherapy. We describe the sleep aid prescribing practices of oncologists treating women adjuvant or neoadjuvant chemotherapy for at single institution.Subjects with early-stage who received four cycles Adriamycin® and cyclophosphamide (AC) University California, San Diego over 2-year period were evaluated by retrospective chart review. Clinical data pertinent to disorders electronic prescriptions aids collected...
Abstract: Genitourinary (GU) cancers are a group of epithelial malignancies associated with the organs involved in excretion urine. Renal cell, urothelial, and prostatic carcinoma overwhelming subtypes diagnosed by oncologists. Each these was traditionally treated surgically when local non-invasive. When carcinomas spread, invade, or metastasize, surgical control lacks efficacy. Chemotherapeutic regimens have been implemented for decades increased overall survival but many patients progress....
This study investigates the association between ABO blood phenotype and COVID-19 severity, measured by intensive care unit admission, need for intubation, hospitalization length death. It further explores clinical predictors of severity within a primarily Hispanic demographic in San Diego County. We retrospectively reviewed 942 total patients, 473 with available type, hospitalized at five Scripps Health hospitals COVID-19. No significant was found on multivariate analysis, while diagnosis...
Collision tumors are uncommon but well described clinical entities composed of distinct tumor histologies occurring within the same anatomic site. Optimal management patients with collision remains highly variable and depends on characteristics such as involved types, predominant histology, extent disease. Comprehensive genomic profiling is a means identifying alterations to suggest benefit from targeted therapy. A 78-year-old woman presented medical oncology liver metastases background...
Aim: To delineate clinical correlates of COVID-19 infection severity in hospitalized patients with malignancy. Methods: The authors conducted a retrospective review all hematologic and/or solid tumor malignancy presenting to the authors' institution between 1 March 2020 and 5 January 2021, laboratory confirmed diagnosis COVID-19. Univariate multivariate logistic regression analyses were used determine associations specific outcomes characteristics. Results: Among 2771 COVID-19, 246 (8.88%)...
: Head and neck squamous cell carcinoma (HNSCC) comprise a diverse group of malignancies including tumors caused by tobacco alcohol as well an increasing number human papillomavirus (HPV)-associated cancers. There has been recent improved understanding on how HNSCC develops evading the immune system. The U.S. Food Drug Administration (FDA) recently granted accelerated approval to checkpoint inhibitor pembrolizumab for treatment recurrent or metastatic HNSCC. We provide comprehensive review...
Journal of Unexplored Medical Data is an open access journal, which considers well-conducted medical science studies, including clinical trials, pilot research reports, original articles, reviews and short communications in the field science.
This retrospective single center study aimed to describe circulating tumor DNA (ctDNA) comprehensive genomic profiling (CGP) utilization in a community practice for patients with advanced solid tumors.All were included who seen at the Scripps Hillcrest Oncology Clinic (San Diego, CA, USA) between September 2016 March 2018 had ctDNA assay testing performed. In this cohort, all was performed aid therapeutic decision making wide variety both type of tumor, as well line therapy.Of assays 41...
<p>Figure S4: ROC overlay demonstrating relationship between FSH values and menopause status. Separate curves were generated for pre (n=333) vs. post (n=317) post/peri (n=390). Subjects who had undergone hysterectomy excluded in these analyses.</p>
<p>Figure S2: Clinical management workflow with inclusion/exclusion criteria for the PDX-002 clinical trial. *Details on malignancy risk from D'Orsi et al.[3]</p>
<p>Figure S1: Breakdown of imaging modalities used to enroll subjects in Provista-002. Some underwent multiple procedures prior enrollment, these are noted side boxes for screening mammogram and diagnostic mammogram.</p>
<p>Figure S5: Individual ROC curves for Videssa Breast model training and validation. Curves shown correspond to those in Fig. 2.</p>
<p>Figure S3: Breakdown of subjects excluded in the Provista-002 trial. Reasons for exclusion shown legend.</p>
<p>Figure S4: ROC overlay demonstrating relationship between FSH values and menopause status. Separate curves were generated for pre (n=333) vs. post (n=317) post/peri (n=390). Subjects who had undergone hysterectomy excluded in these analyses.</p>
<p>Figure S3: Breakdown of subjects excluded in the Provista-002 trial. Reasons for exclusion shown legend.</p>
<p>Figure S1: Breakdown of imaging modalities used to enroll subjects in Provista-002. Some underwent multiple procedures prior enrollment, these are noted side boxes for screening mammogram and diagnostic mammogram.</p>